The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Increase to Block Listing

21 Jan 2021 14:49

RNS Number : 5100M
MaxCyte, Inc.
21 January 2021
 

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

 

Increase to Block Listing,

 

Block Listing Return

 

and

 

Total Voting Rights

 

 

 

MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that application has been made for admission to trading on AIM in respect of an additional block listing of 942,900 common stock of $0.01 each in the capital of the Company ("Common Stock") to become effective on 27 January 2021.

 

The Common Stock may be issued pursuant to the exercise of share options under the Company's Long-Term Incentive Plan (the "LTIP") and will, upon issue, rank pari passu in all respects with the Company's existing Common Stock. Following this increase, the total Block Listing will consist of 1,000,000 Common Stock.

 

 

AIM Block Admission Return

 

MaxCyte also makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.  

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From: 1 July 2020 To: 21 January 2021

 

d. Number and class of securities not issued under scheme

 

319,263 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

262,163 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

57,100 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional block listing application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

 

The total issued stock capital of the Company is 77,422,169 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,522,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.  

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

+1 301 944 1660

 

Date

 

21 January 2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPPUMCGUPGGCG
Date   Source Headline
21st Nov 20197:00 amRNSVor Biopharma Clinical and Commercial License
14th Nov 20197:00 amRNSPresentation at Jefferies Healthcare Conference
7th Nov 20197:00 amRNSMaxCyte to Present at BIO-Europe 2019
1st Nov 20191:04 pmRNSResult of AGM
24th Oct 20197:00 amRNSMaxCyte Advances Phase I Clinical Trial
23rd Oct 20197:01 amRNSPresentations at Cell & Gene Therapy Congress
8th Oct 20197:00 amRNSNotification of AGM and Audit Declaration
7th Oct 20197:00 amRNSEditas Clinical and Commercial License Agreement
30th Sep 20197:00 amRNSUpdates on CARMA Platform at Upcoming Meetings
18th Sep 20197:00 amRNSResults for the Six Months ended 30 June 2019
9th Sep 20197:00 amRNSPresentation at ICLE 2019
14th Aug 20197:00 amRNSNotice of Results
17th Jul 20197:00 amRNSTrading Update
11th Jul 20197:00 amRNSMaxCyte to Host Capital Markets Day Today
5th Jul 20194:42 pmRNSSecond Price Monitoring Extn
5th Jul 20194:36 pmRNSPrice Monitoring Extension
19th Jun 20197:00 amRNSAnnual Report
12th Jun 20197:00 amRNSAppointment of Joint Corporate Broker
29th May 20197:00 amRNSSave the Date: Capital Markets Day
8th May 20194:41 pmRNSSecond Price Monitoring Extn
8th May 20194:36 pmRNSPrice Monitoring Extension
8th May 20197:00 amRNSPhase I Clinical Trial of MCY-M11 Progressed
1st May 20197:00 amRNSASGCT Presentation on First CARMA Drug Candidate
24th Apr 20197:00 amRNSFinal Results for Year Ended 31 December 2018
8th Apr 20197:00 amRNSLaunch of ExPERTT Instrument Family
26th Mar 20197:00 amRNSNotice of Full Year Results
19th Mar 20195:05 pmRNSDirector Dealings
5th Mar 20197:00 amRNSGrant of Options
1st Mar 20197:00 amRNSClinical & Commercial Agreement with Kite
26th Feb 20195:32 pmRNSResult of Special Meeting and Issue of Equity
5th Feb 20194:32 pmRNSResults of Placing
5th Feb 20197:00 amRNSProposed Placing to raise a minimum of £10 million
15th Jan 20197:00 amRNSTrading Update
19th Dec 20187:00 amRNSChange of Auditor
17th Dec 20186:06 pmRNSDirector Dealings
21st Nov 20187:00 amRNSConsolidation of Trading Lines
20th Nov 20187:00 amRNSBlock Admission Six Monthly Return/TVR
16th Nov 20187:00 amRNSWebinar: non-viral cell engineering
14th Nov 20187:00 amRNSClinical and Commercial License Agreement
12th Nov 20187:00 amRNSMaxCyte Announces Research Agreement with Kite
9th Nov 20187:00 amRNSExpansion of CRISPR Commercial License Agreement
31st Oct 20184:25 pmRNSResult of AGM
10th Oct 20187:00 amRNSDosing Begins in First Clinical Trial of MCY-M11
8th Oct 20187:00 amRNSNotice of AGM
24th Sep 20187:00 amRNSResults for the Half Year ended 30 June 2018
10th Sep 20187:00 amRNSGrant of Options
3rd Sep 20187:00 amRNSNotice of Half Year Results
26th Jul 20185:33 pmRNSDirector/PDMR Shareholding
16th Jul 20187:00 amRNSFDA IND Clearance for First Clinical Programme
16th Jul 20187:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.